' 
![]()
SCIENTIFIC SCORE
Possibly Effective
Based on 32 Researches
7.1
USERS' SCORE
Good
Based on 3 Reviews
8.4
Supplement Facts
Serving Size: 2 Softgels
Amount Per Serving
%DV
Calories
20
Total Fat
2 g
3%**
Saturated Fat
0.5 g
3%**
Polyunsaturated Fat
1 g
†
Monounsaturated Fat
0.5 g
†
Fish Oil Concentrate
2 g (2,000 mg)
†
Eicosapentaenoic Acid (EPA)
360 mg
†
Docosahexaenoic Acid (DHA)
240 mg
†
Top Medical Research Studies
8
Eicosapentaenoic acid's anti-cancer effects
Contribution of Pyk2 pathway and reactive oxygen species (ROS) to the anti-cancer effects of eicosapentaenoic acid (EPA) in PC3 prostate cancer cells.
Direct effects on prostate cancer
We investigated how eicosapentaenoic acid (EPA) influences prostate cancer cells, particularly focusing on its effects on PC3 prostate cancer cells. To understand this, we treated the cells with various concentrations of EPA and monitored their survival, migration, and invasion abilities over time.
Our findings revealed that EPA reduces the survival rate of PC3 cells in a dose-dependent manner, showing significant effectiveness at a concentration of 500 μmol/L within just three hours of treatment. Moreover, we observed that EPA inhibits key cellular pathways linked to cancer cell growth, particularly the phosphorylation of a protein known as Pyk2. Interestingly, even though EPA affected Pyk2, this action occurred independently of reactive oxygen species (ROS) production, while growth inhibition appeared to depend significantly on the induction of ROS.
Overall, our research highlighted how the combined inhibition of Pyk2 and ROS contribute to the anti-cancer properties of EPA. This suggests that EPA could be a valuable component in therapeutic strategies for combating prostate cancer.
Our findings revealed that EPA reduces the survival rate of PC3 cells in a dose-dependent manner, showing significant effectiveness at a concentration of 500 μmol/L within just three hours of treatment. Moreover, we observed that EPA inhibits key cellular pathways linked to cancer cell growth, particularly the phosphorylation of a protein known as Pyk2. Interestingly, even though EPA affected Pyk2, this action occurred independently of reactive oxygen species (ROS) production, while growth inhibition appeared to depend significantly on the induction of ROS.
Overall, our research highlighted how the combined inhibition of Pyk2 and ROS contribute to the anti-cancer properties of EPA. This suggests that EPA could be a valuable component in therapeutic strategies for combating prostate cancer.
Read More
8
Eicosapentaenoic Acid Reduces Prostate Cancer
Inhibition of PC3 human prostate cancer cell proliferation, invasion and migration by eicosapentaenoic acid and docosahexaenoic acid.
Directly addresses EPA's effects
We investigated how eicosapentaenoic acid (EPA), a key omega-3 fatty acid found in fish oil, affects prostate cancer cells, particularly the aggressive PC3 cells that are resistant to conventional treatments. By exposing these cells to different concentrations of EPA, we aimed to uncover its potential as a new treatment for castration-resistant prostate cancer.
Our findings indicated that EPA significantly decreased both the proliferation and the ability of PC3 cells to invade and migrate. This effect was not only dose-dependent but particularly pronounced at concentrations of 100 and 200 µg/ml. Interestingly, while lower doses of EPA (25 µg/ml) had minimal impact on cell behavior, we noted a clear reduction in cancer cell migration and invasion with higher doses (50 µg/ml).
Importantly, we also observed similar beneficial effects with docosahexaenoic acid (DHA), another omega-3 fatty acid, which mirrored EPA's influence on these cancerous cells. Overall, both EPA and DHA showcase promise in slowing down the growth and spread of prostate cancer, although the specific mechanisms behind these effects remain to be fully explored.
Our findings indicated that EPA significantly decreased both the proliferation and the ability of PC3 cells to invade and migrate. This effect was not only dose-dependent but particularly pronounced at concentrations of 100 and 200 µg/ml. Interestingly, while lower doses of EPA (25 µg/ml) had minimal impact on cell behavior, we noted a clear reduction in cancer cell migration and invasion with higher doses (50 µg/ml).
Importantly, we also observed similar beneficial effects with docosahexaenoic acid (DHA), another omega-3 fatty acid, which mirrored EPA's influence on these cancerous cells. Overall, both EPA and DHA showcase promise in slowing down the growth and spread of prostate cancer, although the specific mechanisms behind these effects remain to be fully explored.
Read More
4
Eicosapentaenoic acid effects studied
Effects of concentrated long-chain omega-3 polyunsaturated fatty acid supplementation before radical prostatectomy on prostate cancer proliferation, inflammation, and quality of life: study protocol for a phase IIb, randomized, double-blind, placebo-controlled trial.
Highly relevant study on prostate cancer
This study investigates the effects of eicosapentaenoic acid (EPA) supplementation on men with prostate cancer. Specifically, we designed a phase IIb clinical trial where participants received either EPA or a placebo in the form of high oleic acid sunflower oil. This trial involved 130 men who were preparing for radical prostatectomy, a common surgical treatment for prostate cancer.
Our approach included randomizing participants to ensure that neither the researchers nor the participants knew who was receiving the active treatment or the placebo, which helps to eliminate bias. We aimed to measure how the EPA affected cancer cell growth by looking at the proliferative index in prostate tissue during surgery. Additionally, we evaluated inflammation levels in prostate tissues and blood, as well as assessed quality of life factors like mood and sleep over a year following surgery.
We look forward to gaining insights from this trial that may clarify whether EPA supplementation can genuinely affect prostate cancer proliferation, inflammation, and ultimately the quality of life for those undergoing treatment. The findings could provide meaningful guidance for dietary interventions in prostate cancer management.
Our approach included randomizing participants to ensure that neither the researchers nor the participants knew who was receiving the active treatment or the placebo, which helps to eliminate bias. We aimed to measure how the EPA affected cancer cell growth by looking at the proliferative index in prostate tissue during surgery. Additionally, we evaluated inflammation levels in prostate tissues and blood, as well as assessed quality of life factors like mood and sleep over a year following surgery.
We look forward to gaining insights from this trial that may clarify whether EPA supplementation can genuinely affect prostate cancer proliferation, inflammation, and ultimately the quality of life for those undergoing treatment. The findings could provide meaningful guidance for dietary interventions in prostate cancer management.
Read More
Most Useful Reviews
8
Helpful for father
I purchased this pill based on my friend's recommendation for my father's prostate cancer issue. The ingredients should be beneficial for him, although it does taste of fish.
Read More
8.8
Effective Omega supplement
I have been taking NOW Brand Omega 3-6-9 for 18 years, but due to being prescribed Tamoxifen after breast cancer, I had to stop all but Omega 3. I switched to these capsules, and they are nearly as good as the 3-6-9 blend. I plan to return to the 3-6-9 once I finish Tamoxifen.
Read More
7.3
Supports prostate health
High-quality fish oil Omega 3 is an essential supplement, especially for women, as it reduces inflammation, maintains youthful skin, and strengthens hair. It also normalises reproductive health and lowers the risk of prostate cancer. The DHA and EPA content is low, and the recommended dosage is two capsules twice daily, which I find inconvenient. I prefer taking three capsules after breakfast, making the supply last a month. While the capsules are relatively large, I have no issues swallowing them.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 32 Researches
7.1
9
DHA's impact on prostate cancer
The polyunsaturated fatty acid docosahexaenoic affects mitochondrial function in prostate cancer cells.
Highly relevant to prostate cancer
We explored how docosahexaenoic acid (DHA), a type of omega-3 polyunsaturated fatty acid, influences prostate cancer cells. In our investigation, we focused on different prostate cell lines, including both non-malignant and castration-resistant types. By utilizing various techniques, such as Seahorse assays to examine mitochondrial function and other methods to assess cell health, we aimed to uncover the details of DHA's effects.
Our findings revealed that DHA significantly impacts mitochondrial metabolism in prostate cancer cells. Notably, cells exposed to DHA struggled to survive or grow, highlighting its potential anti-cancer properties. While this fatty acid alone appears beneficial, our results suggest that pairing DHA with the inhibition of certain metabolic pathways might lead to even more pronounced effects, particularly in castration-resistant prostate cancer cases.
These insights into DHA's function provide a promising direction for future research into cancer treatments, potentially paving the way for innovative strategies to combat prostate cancer more effectively.
Our findings revealed that DHA significantly impacts mitochondrial metabolism in prostate cancer cells. Notably, cells exposed to DHA struggled to survive or grow, highlighting its potential anti-cancer properties. While this fatty acid alone appears beneficial, our results suggest that pairing DHA with the inhibition of certain metabolic pathways might lead to even more pronounced effects, particularly in castration-resistant prostate cancer cases.
These insights into DHA's function provide a promising direction for future research into cancer treatments, potentially paving the way for innovative strategies to combat prostate cancer more effectively.
Read More
9
DHA enhances chemotherapy effectiveness
Docosahexaenoic Acid Reverses Epithelial-Mesenchymal Transition and Drug Resistance by Impairing the PI3K/AKT/ Nrf2/GPX4 Signalling Pathway in Docetaxel-Resistant PC3 Prostate Cancer Cells.
Moderately relevant to prostate cancer
We sought to understand whether docosahexaenoic acid (DHA) could reverse docetaxel resistance in prostate cancer cells. Through various tests, including cell survival assays and protein expression analysis, we examined how DHA impacts the survival and behavior of prostate cancer cells.
Our findings revealed that DHA effectively inhibits cancer cell growth, migration, and promotes apoptosis (cell death). We also discovered that DHA can induce changes in the cells, making them less resistant to treatment. Notably, DHA regulates important proteins involved in drug resistance and impacts cellular processes like autophagy and ferroptosis.
By combining DHA with a common chemotherapy drug, docetaxel, we were able to enhance cancer-fighting effects and inhibit processes associated with tumor growth. Our research points to the potential of DHA as a complementary treatment to conventional therapies, suggesting it may make prostate cancer cells more responsive to drugs.
Overall, we believe DHA could serve as a promising agent in tackling drug resistance in prostate cancer, opening new avenues for more effective treatments.
Our findings revealed that DHA effectively inhibits cancer cell growth, migration, and promotes apoptosis (cell death). We also discovered that DHA can induce changes in the cells, making them less resistant to treatment. Notably, DHA regulates important proteins involved in drug resistance and impacts cellular processes like autophagy and ferroptosis.
By combining DHA with a common chemotherapy drug, docetaxel, we were able to enhance cancer-fighting effects and inhibit processes associated with tumor growth. Our research points to the potential of DHA as a complementary treatment to conventional therapies, suggesting it may make prostate cancer cells more responsive to drugs.
Overall, we believe DHA could serve as a promising agent in tackling drug resistance in prostate cancer, opening new avenues for more effective treatments.
Read More
9
Didocosahexaenoin shows promise against prostate cancer
Investigation of the cytotoxicity induced by didocosahexaenoin, an omega 3 derivative, in human prostate carcinoma cell lines.
Highly relevant to prostate cancer research
We examined the effects of didocosahexaenoin (Dido), a derivative of omega-3 fatty acids, on human prostate cancer cells. Specifically, we aimed to understand its cytotoxicity and how it compares to docosahexaenoic acid (DHA), another compound from the same family. Our research involved exposing different types of cells to varying concentrations of these omega-3 compounds for different lengths of time.
In our observations, Dido showed stronger cytotoxic effects on prostate carcinoma cells than DHA. Notably, the effects of Dido were dose-dependent and timed, indicating that higher concentrations and longer exposure times amplified its impact. Furthermore, Dido demonstrated a remarkable selectivity towards prostate cancer cells when compared to other carcinoma cell lines, making it a promising candidate for targeted treatment.
We also identified some interesting mechanisms behind Dido's effect. Pre-treatment with Dido significantly increased the levels of reactive oxygen species (ROS) in the prostate cancer cells. This rise in ROS seemed to trigger apoptosis, or programmed cell death, evidenced by several key changes in the cells. For instance, we noted an increase in phosphatidyl serine externalization and changes in mitochondrial membrane potential alongside heightened caspase 3/7 activity—a marker of apoptosis.
Ultimately, our study highlights the potential of Dido as a more potent and selective agent than DHA for targeting prostate cancer. These findings suggest that Dido could be an advantageous addition to existing therapies, particularly in combination with traditional chemotherapy options.
In our observations, Dido showed stronger cytotoxic effects on prostate carcinoma cells than DHA. Notably, the effects of Dido were dose-dependent and timed, indicating that higher concentrations and longer exposure times amplified its impact. Furthermore, Dido demonstrated a remarkable selectivity towards prostate cancer cells when compared to other carcinoma cell lines, making it a promising candidate for targeted treatment.
We also identified some interesting mechanisms behind Dido's effect. Pre-treatment with Dido significantly increased the levels of reactive oxygen species (ROS) in the prostate cancer cells. This rise in ROS seemed to trigger apoptosis, or programmed cell death, evidenced by several key changes in the cells. For instance, we noted an increase in phosphatidyl serine externalization and changes in mitochondrial membrane potential alongside heightened caspase 3/7 activity—a marker of apoptosis.
Ultimately, our study highlights the potential of Dido as a more potent and selective agent than DHA for targeting prostate cancer. These findings suggest that Dido could be an advantageous addition to existing therapies, particularly in combination with traditional chemotherapy options.
Read More
9
Docosahexaenoic acid enhances cilproflxacin cytotoxicity
The Effect of Fatty Acids on Ciprofloxacin Cytotoxic Activity in Prostate Cancer Cell Lines-Does Lipid Component Enhance Anticancer Ciprofloxacin Potential?
Evaluates dual compound effects
We examined how docosahexaenoic acid (DHA) affects prostate cancer cells when combined with ciprofloxacin, an antibiotic known for its potential anti-cancer properties. Our focus was on two different prostate cancer cell lines: LNCaP, which is hormone-sensitive, and DU-145, which is hormone-resistant. By looking at the outcome of these combinations, we aimed to determine whether DHA could enhance the overall effectiveness of ciprofloxacin.
During our experiments, we found that the conjugates of ciprofloxacin and fatty acids, including DHA, had a pronounced cytotoxic effect on the DU-145 cell line, with an IC50 value of 16.5 µM. This means that a concentration of 16.5 µM of the compound was able to kill half of the DU-145 cells, indicating significant potential. In contrast, the hormone-sensitive LNCaP cells demonstrated reduced sensitivity, with IC50 values exceeding 20 µM.
We also noticed that these conjugates decreased IL-6 release—an important marker in cancer progression—by nearly 50% across both cell lines. Interestingly, while early apoptosis was predominant in LNCaP cells, both early and late apoptosis were observed in DU-145 cells, revealing a more complex response to the treatment in hormone-insensitive cells.
Overall, the results of our study suggest that coupling ciprofloxacin with DHA may bolster the drug's anticancer benefits, particularly in certain types of prostate cancer cells. However, the distinct responses of the two cell lines prompt further investigation to clarify the mechanisms at play.
During our experiments, we found that the conjugates of ciprofloxacin and fatty acids, including DHA, had a pronounced cytotoxic effect on the DU-145 cell line, with an IC50 value of 16.5 µM. This means that a concentration of 16.5 µM of the compound was able to kill half of the DU-145 cells, indicating significant potential. In contrast, the hormone-sensitive LNCaP cells demonstrated reduced sensitivity, with IC50 values exceeding 20 µM.
We also noticed that these conjugates decreased IL-6 release—an important marker in cancer progression—by nearly 50% across both cell lines. Interestingly, while early apoptosis was predominant in LNCaP cells, both early and late apoptosis were observed in DU-145 cells, revealing a more complex response to the treatment in hormone-insensitive cells.
Overall, the results of our study suggest that coupling ciprofloxacin with DHA may bolster the drug's anticancer benefits, particularly in certain types of prostate cancer cells. However, the distinct responses of the two cell lines prompt further investigation to clarify the mechanisms at play.
Read More
8
Eicosapentaenoic acid affects PCa
Global acetylome profiling indicates EPA impedes but OA promotes prostate cancer motility through altered acetylation of PFN1 and FLNA.
Direct investigation of EPA's effects
We explored the effects of fatty acids on prostate cancer (PCa) cells, specifically focusing on eicosapentaenoic acid (EPA). We observed that EPA, a type of omega-3 fatty acid, has a notable impact on cancer cell movement and invasion.
Our study revealed that EPA lowers acetyl-CoA levels in the cells, which leads to changes in the global acetylation profile. This is crucial because acetylation plays a role in regulating proteins involved in cell motility. We specifically found that EPA decreases the acetylation of PFN1, a protein associated with cell movement.
As a result, we noted that EPA inhibits the migration and invasion of PCa cells. This was corroborated by immunofluorescence assays, which showed that EPA reduces the formation of cellular extensions known as lamellipodia and filopodia. In contrast, oleic acid, another fatty acid we tested, increased acetylation and promoted cell motility.
Collectively, our findings offer new insights into how omega-3 fatty acids like EPA may influence prostate cancer progression by altering protein acetylation and, ultimately, cell movement.
Our study revealed that EPA lowers acetyl-CoA levels in the cells, which leads to changes in the global acetylation profile. This is crucial because acetylation plays a role in regulating proteins involved in cell motility. We specifically found that EPA decreases the acetylation of PFN1, a protein associated with cell movement.
As a result, we noted that EPA inhibits the migration and invasion of PCa cells. This was corroborated by immunofluorescence assays, which showed that EPA reduces the formation of cellular extensions known as lamellipodia and filopodia. In contrast, oleic acid, another fatty acid we tested, increased acetylation and promoted cell motility.
Collectively, our findings offer new insights into how omega-3 fatty acids like EPA may influence prostate cancer progression by altering protein acetylation and, ultimately, cell movement.
Read More
User Reviews
USERS' SCORE
Good
Based on 3 Reviews
8.4
8.8
Effective Omega supplement
I have been taking NOW Brand Omega 3-6-9 for 18 years, but due to being prescribed Tamoxifen after breast cancer, I had to stop all but Omega 3. I switched to these capsules, and they are nearly as good as the 3-6-9 blend. I plan to return to the 3-6-9 once I finish Tamoxifen.
8
Helpful for father
I purchased this pill based on my friend's recommendation for my father's prostate cancer issue. The ingredients should be beneficial for him, although it does taste of fish.
7.3
Supports prostate health
High-quality fish oil Omega 3 is an essential supplement, especially for women, as it reduces inflammation, maintains youthful skin, and strengthens hair. It also normalises reproductive health and lowers the risk of prostate cancer. The DHA and EPA content is low, and the recommended dosage is two capsules twice daily, which I find inconvenient. I prefer taking three capsules after breakfast, making the supply last a month. While the capsules are relatively large, I have no issues swallowing them.
Read More
